SCHEMBL1703971

SCHEMBL1703971

C[C@]1(Cc2ccccc2)CN(Cc2ccc(Br)cc2)CCN1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
LMNA P02545 2/20 0.51
HPGD P15428 2/20 0.51
HTT P42858 1/20 0.51
MAPK1 P28482 2/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
MAPT P10636 1/20 0.49
CYP2C19 P33261 1/20 0.49
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
FAAH O00519 1/20 0.46
KDM4E B2RXH2 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPC1 O15118 1/20 0.45
DUSP3 P51452 1/20 0.45
PTPN5 P54829 1/20 0.45
PTPN11 Q06124 1/20 0.45
SIGMAR1 Q99720 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1633895 0.88 KDM4E (0.51) ALDH1A1LMNAHTTMAPK1CYP3A4
SCHEMBL1703908 0.84 ALDH1A1 (0.43) ALDH1A1LMNAHPGDHTTCYP2D6
SCHEMBL14813579 0.78 GAA (0.50) ALDH1A1LMNACYP3A4CYP2D6MEN1
SCHEMBL2007650 0.77 POLB (0.39) ALDH1A1LMNAMAPK1CYP3A4CYP2D6
SCHEMBL5619307 0.77 OPRM1 (0.40) ALDH1A1CYP2D6SMN1; SMN2NPC1
SCHEMBL1188920 0.75 MEN1 (0.48) ALDH1A1HTTMEN1KMT2AKDM4E
SCHEMBL1631552 0.74 CHRM3 (0.40) KCNH2CHRM2CHRM3
SCHEMBL1704166 0.74 KDM4E (0.40) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL3495126 0.73 LMNA (0.44) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL31198934 0.72 SIGMAR1 (0.75) ALDH1A1LMNAHPGDHTTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441763-A1 Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders Glaxo Group Limited (GB) 2012-04-18 EP disclosed